Friday, April 3, 2026
30.4 C
Bengaluru

7 Transitions in Leadership for Indian Pharma Leaders

The rapid pace of change, which began in 2020 is unrelenting and ongoing. The high-stakes game has made many pharma leaders play defensive, instead of using the crisis to bring in the much-needed transformational changes.

Leaders continue to rely on the traditional time-tested strategies, so that they can avoid the embarrassment of ‘losing’ in this high-stakes game. Most prefer to keep doing something they know to do well. We all like to do what we are good at, and are comfortable with. Most leaders are happy to be ‘nest-building’ and remain in their comfort zones.

There are several research findings, suggesting that to make the transition successfully, leaders must navigate a tricky set of changes in their leadership focus and skills.

Here are the seven shifts that leaders must understand and adapt:

  1. Move from, Specialist to Generalist
  2. Analyst to Integrator
  3. Tactician to Strategist
  4. Bricklayer to Architect
  5. Problem solver to Agenda setter
  6. Warrior to Diplomat, and 
  7. Supporting cast member to the Lead role

Digital Excellence Pharma Academy – DEPA, a joint initiative of CredoWeb and MedicinMan has put together 4 learning modules that will enable pharma professionals to be successful in the New Normal.

Register now on https://www.credoweb.in/discussion/588/7-role-transitions-for-pharma-leaders-key-lessons-from-sanjiv-navangul to listen Deep Bhandari explain the 7 Transitions in Leaders and the Key Lessons from Sanjiv Navangul’s session.

Hot this week

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...
spot_img

Related Articles

spot_imgspot_img